Literature DB >> 33262450

Cross-viral protection against SARS-CoV-2?

Sophie G Reed1.   

Abstract

Entities:  

Year:  2021        PMID: 33262450      PMCID: PMC7706172          DOI: 10.1038/s41577-020-00483-x

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   108.555


× No keyword cloud information.
T cell cross-reactivity against SARS-CoV-2 has previously been shown in unexposed individuals. These T cells are thought to arise through exposure to other related coronaviruses such as those causing the common cold. In this preprint, Mahajan et al. used the algorithm ‘OncoPeptVAC’ to predict SARS-CoV-2 immunodominant peptides, some of which induced in vitro responses by T cells isolated from both healthy, unexposed individuals and convalescent patients. The predicted epitopes induced higher levels of CD8+ T cell activation than did overlapping peptide pools of spike protein. T cell receptor (TCR) repertoire profiling of peptide-expanded cultures showed clonal expansion of multiple public TCR sequences recognizing peptides from HCMV, HHV-5 and influenza A virus. This suggests that exposure to these other viruses induces SARS-CoV-2-reactive T cells, which may confer protection against COVID-19.
  1 in total

1.  Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals.

Authors:  Swapnil Mahajan; Vasumathi Kode; Keshav Bhojak; Coral Karunakaran; Kayla Lee; Malini Manoharan; Athulya Ramesh; Sudheendra Hv; Ankita Srivastava; Rekha Sathian; Tahira Khan; Prasanna Kumar; Ravi Gupta; Papia Chakraborty; Amitabha Chaudhuri
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.